John Andenoro, MD
Urology · Kalispell, MTNPI 1518058551
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Neotract Inc. at 50.3% of the total. Reporting peaked in 2019 at $1,637 and has fallen 81.4% since, to $304 in 2025.
Across 62 payments — averaging $41.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$1K
- Astellas Pharma US Inc$311
- Johnson & Johnson$145
- AbbVie$129
- Davol Inc.$114
- Boston Scientific$80
- plus $497 from 19 others
What the payments were for
- Travel & lodging$1,12644%
- Food & beverage$1,22948%
- Education$2108%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 7 | $1,289 |
| Astellas Pharma US Inc | 9 | $311 |
| Johnson & Johnson | 7 | $145 |
| AbbVie | 6 | $129 |
| Davol Inc. | 1 | $114 |
| Boston Scientific | 4 | $80 |
| Bayer | 4 | $70 |
| Dendreon Pharmaceuticals LLC | 3 | $63 |
| Teleflex LLC | 2 | $48 |
| Amgen | 2 | $36 |
| Laborie Medical Technologies Corp. | 3 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Conmed Corporation | 1 | $27 |
| Myovant Sciences Inc. | 1 | $23 |
| 180 Medical, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Immunitybio, Inc. | 1 | $17 |
| Profound Medical Corp. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Innovation Technologies Inc | 1 | $14 |
| Medtronic | 1 | $14 |
| Pfizer | 1 | $13 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,565 in reported general payments places this provider in the 60th percentile of 45 urology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 19 | $14,310 |
| MyrbetriqMirabegron | 15 | $12,052 |
| Tamsulosin Hcl | 142 | $1,660 |
| Methenamine Hippurate | 21 | $908 |
| Solifenacin Succinate | 38 | $893 |
| Finasteride | 54 | $772 |
| Oxybutynin Chloride | 67 | $513 |
| Doxycycline Hyclate | 14 | $439 |
| Megestrol Acetate | 11 | $297 |
| Cephalexin | 69 | $210 |
| Ciprofloxacin Hcl | 32 | $184 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $160 |
| Tramadol Hcl | 56 | $115 |
| Ibuprofen | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $27 | $14,31019 claims |
| Astellas Pharma US IncMyrbetriq | $311 | $12,05215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 45 urology providers in Montana.
Other urology in Kalispell
- Amy McKerrowKalispell$9K
- Sarabeth MartinKalispell$4K
- Geraldine SheuKalispell$2K
- Jonathan MercerKalispell$2K
- Vassilis SiomosKalispell$2K
- Gregory AdamsKalispell$669
- Michael BersonKalispell$95
- Craig HinmanKalispell$29
- Christopher FukudaGreat Falls$19K
- Garrick SimmonsMissoula$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.